Atlas Trials

Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study

Clinical trial NCT05638438 · UNKNOWN

Trial details

NCT number
NCT05638438
Sponsor
Zhujiang Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
Hepatocellular Carcinoma Non-resectable
Start date
2022-12-02
Primary completion
2023-06-30
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.